An Act to amend and reenact § 54.1-3304.1 of the Code of Virginia and to amend the Code of Virginia by adding a section numbered 54.1-3222.1, relating to TPA-certified optometrists; selling and dispensing Schedule VI controlled substances; requirements.
HB1006 authorizes TPA-certified optometrists in Virginia to sell and dispense certain Schedule VI controlled substances directly to their own patients for treatment of conditions of the eye and adnexa, so long as the optometrist is already authorized to prescribe the medication and complies with new licensing and practice requirements. The bill adds a new Code section establishing detailed conditions for dispensing, including Board of Pharmacy licensure, Department of Health Professions inspection authority, the optometrist’s presence during dispensing, patient counseling, and compliance with storage, labeling, recordkeeping, and reporting rules.
The bill also amends the existing practitioner-dispensing statute to expressly allow the Board of Pharmacy to issue a limited-use license to a TPA-certified optometrist for dispensing and selling Schedule VI controlled substances consistent with the new section. It limits dispensing to finished pharmaceutical products in original, unaltered form, and specifically bars compounding, repackaging, or other alteration. The measure clarifies that it does not expand an optometrist’s broader administrative or prescriptive authority beyond what is already authorized under Virginia law.
HB1006 changes Virginia’s drug-dispensing and professional-licensing framework by creating a new statutory pathway for certain optometrists to dispense Schedule VI controlled substances and by directing the Board of Pharmacy and Board of Optometry to regulate that activity. It affects the Code of Virginia provisions governing practitioner dispensing, pharmacy licensure, controlled substances, and optometry practice, while also giving regulators inspection and rulemaking authority over optometrists who participate in dispensing.
The available record shows no committee transcript or recorded vote history, so there is no direct evidence of debate or opposition in the provided materials. The bill’s enactment as Chapter 929 suggests it ultimately received sufficient support to pass and become law. Based on the text, the measure appears to be a targeted professional-practice expansion with significant regulatory safeguards, which may have made it more acceptable to stakeholders concerned about patient access and controlled-substance oversight.
The main likely point of contention is whether optometrists should be allowed to dispense controlled substances at all, even in a limited setting, because the bill expands their role into medication dispensing while insisting that it does not expand their underlying prescriptive authority. Another possible concern is regulatory oversight: the bill requires Board of Pharmacy licensure, inspections, and compliance with pharmacy-style storage and recordkeeping rules, which may raise administrative burdens for optometrists and enforcement questions for regulators. The bill also narrowly limits the authority to Schedule VI products, original manufacturer packaging, and treatment of eye-related conditions, indicating an effort to balance access with caution.